Find Clinical Trials

All CategoriesMedical Conditions»Blood Disorders»Anemia»Aplastic Anemia



Join Paid Clinical Trials



  • Condition:   Severe Aplastic Anemia
    Interventions:   Drug: Thymoglobulin;   Procedure: Cord blood;   Drug: Cyclosporine Oral Product
    Sponsors:   Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine;   Ruijin Hospital;   Xinhua Hospital, Shanghai Jiao Tong University School of Medicine;   Shanghai Tongji Hospital, Tongji University School of Medicine;   Zhejiang Provincial Hospital of TCM
    Recruiting

  • Condition:   Severe Aplastic Anemia
    Interventions:   Drug: Antithymocyte Globulin (ATG);   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation (TBI);   Procedure: Haplo HSCT;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil (MMF);   Drug: G-CSF
    Sponsors:   Medical College of Wisconsin;   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI);   Blood and Marrow Transplant Clinical Trials Network;   National Marrow Donor Program
    Recruiting

  • Condition:   Aplastic Anemia
    Intervention:   Drug: Combination of thrombopoietin mimetic and cyclosporin A
    Sponsors:   Safaa AA Khaled;   Assiut University
    Not yet recruiting

  • Condition:   Aplastic Anemia
    Interventions:   Drug: Eltrombopag;   Drug: hATG;   Drug: CsA
    Sponsor:   Novartis Pharmaceuticals
    Recruiting

  • Condition:   Severe Aplastic Anemia
    Interventions:   Drug: eltrombopag;   Drug: Cyclosporine
    Sponsor:   Novartis Pharmaceuticals
    Recruiting

  • Condition:   Severe Aplastic Anemia
    Interventions:   Drug: Hetrombopag Olamine+Standard Therapy;   Drug: Placebo+Standard Therapy
    Sponsor:   Jiangsu HengRui Medicine Co., Ltd.
    Not yet recruiting

  • Condition:   Severe Aplastic Anemia
    Intervention:   Drug: Hetrombopag Olamine
    Sponsor:   Jiangsu HengRui Medicine Co., Ltd.
    Not yet recruiting

  • Condition:   Severe Aplastic Anemia
    Interventions:   Drug: cyclosporine;   Procedure: Matched Unrelated Donor Hematopoietic Stem Cell Transplant;   Drug: horse anti-thymocyte globulin (ATG);   Drug: rabbit anti-thymocyte globulin (ATG);   Drug: methotrexate;   Drug: fludarabine;   Drug: cyclophosphamide;   Radiation: low-dose total body irradiation (TBI);   Procedure: Immunosuppressive Therapy (IST)
    Sponsor:   Michael Pulsipher, MD
    Recruiting

  • Condition:   Severe Aplastic Anemia
    Interventions:   Drug: Non ATG Conditioning regimen;   Drug: GVHD Prophylaxis;   Procedure: Allogenic Stem Cell Transplantation;   Drug: ATG conditioning regimen
    Sponsor:   Assiut University
    Not yet recruiting

  • Condition:   Severe Aplastic Anemia
    Intervention:   Drug: Sirolimus
    Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Condition:   Severe Aplastic Anemia
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation;   Drug: Rabbit ATG
    Sponsor:   Northside Hospital, Inc.
    Recruiting

  • Condition:   Severe Aplastic Anemia
    Interventions:   Drug: hATG/CsA /eltrombopag -Cohort1;   Drug: hATG/CsA /eltrombopag Cohort 2;   Drug: hATG/CsA /eltrombopag Cohort 3
    Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Conditions:   Dyskeratosis Congenita;   Aplastic Anemia
    Interventions:   Drug: Alemtuzumab;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation;   Biological: Stem Cell Transplant;   Drug: Anti-thymocyte globulin
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Severe Aplastic Anemia;   MDS (Myelodysplastic Syndrome)
    Interventions:   Device: Miltenyi CD34 Reagent System;   Other: Donor derived G-CSF mobilized PBC
    Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Conditions:   Severe Aplastic Anemia;   Bone Marrow Failure Syndromes
    Interventions:   Procedure: Bone marrow transplant;   Drug: Thymoglobulin;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: TBI;   Drug: Mesna;   Drug: Tacrolimus;   Drug: Mycophenolic acid mofetil
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Recruiting

  • Conditions:   Severe Aplastic Anemia (SAA);   Hypo-Plastic Myelodysplastic Syndrome (MDS)
    Intervention:   Procedure: haplo-identical transplantation
    Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Condition:   Severe Aplastic Anemia
    Interventions:   Drug: hATG;   Drug: CsA;   Drug: Eltrombopag
    Sponsors:   European Group for Blood and Marrow Transplantation;   Novartis;   Pfizer
    Recruiting

  • Conditions:   Myelodysplastic Syndrome (MDS);   Severe Aplastic Anemia (SAA)
    Interventions:   Other: Umbilical Cord Blood;   Other: Haploidentical Stem Cells;   Device: Miltenvi CliniMACs CD34 Reagent System
    Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Conditions:   Severe Aplastic Anemia;   Aplastic Anemia;   Bone Marrow Failure;   Immunosuppression
    Interventions:   Drug: Thymoglobulin;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total body irradiation;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Recruiting

  • Conditions:   Severe Aplastic Anemia;   Hypo-Plastic MDS;   Myelodysplastic Syndrome (MDS)
    Intervention:   Biological: CordIn
    Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Condition:   Eltrombopag
    Intervention:   Drug: Eltrombopag
    Sponsor:   Assiut University
    Recruiting

  • Condition:   Leukemia
    Interventions:   Drug: hATG;   Drug: Cyclosporine;   Drug: Methylprednisone;   Drug: Pegfilgrastim;   Drug: Filgrastim
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting

  • Condition:   Myeloid Diseases
    Interventions:   Drug: Antithymocyte globulin (Rabbit);   Drug: fludarabine;   Radiation: total body irradiation;   Drug: cyclophosphamide;   Drug: Rituxan;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Conditions:   Aplastic Anemia;   Stem Cell Transplant Complications;   Engraft Failure
    Intervention:   Drug: Fludarabine
    Sponsor:   Peking University People's Hospital
    Recruiting

  • Conditions:   Fanconi Anemia;   Severe Aplastic Anemia;   Myelodysplastic Syndromes
    Interventions:   Drug: Total Body Irradiation (TBI) (Plan 1);   Drug: Cyclophosphamide (CY) (Plan 1);   Drug: Fludarabine (FLU);   Drug: Methylprednisolone (MP);   Device: Donor mobilized PBSC infusion;   Drug: G-CSF;   Drug: Cyclophosphamide (CY) (Plan 2);   Drug: Rituximab
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Acquired Aplastic Anemia;   Paroxysmal Nocturnal Hemoglobinuria;   Inherited Bone Marrow Failure Syndromes
    Intervention:   Device: CliniMACs
    Sponsor:   Children's Hospital of Philadelphia
    Recruiting

  • Conditions:   Immunodeficiency Syndrome;   Non-Cancer Diagnosis;   Severe Aplastic Anemia
    Interventions:   Procedure: Allogeneic Bone Marrow Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Sirolimus;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Condition:  
    Intervention:   Drug: Itacitinib
    Sponsor:   Incyte Corporation
    Available

  • Conditions:   Dyskeratosis Congenita;   Hoyeraal Hreidarsson Syndrome;   Revesz Syndrome;   Aplastic Anemia
    Interventions:   Biological: alemtuzumab;   Drug: Fludarabine;   Drug: Cyclosporins;   Drug: Mycophenolate mofetil
    Sponsors:   Boston Children’s Hospital;   Dana-Farber Cancer Institute;   Children's Hospital Medical Center, Cincinnati;   Children's Hospital Los Angeles;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   Baylor College of Medicine;   Children's Hospital of Philadelphia;   Memorial Sloan Kettering Cancer Center;   University of Wisconsin, Madison;   Karolinska University Hospital
    Recruiting

  • Conditions:   Aplastic Anemia;   Leukemia;   Myelodysplastic Syndrome (MDS);   Lymphoma
    Intervention:   Biological: Cord Blood Units
    Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI);   National Institute of Allergy and Infectious Diseases (NIAID);   National Cord Blood Program, New York Blood Center
    Recruiting

  • Conditions:   Thrombocytopenia;   Hematologic Diseases;   Bone Marrow Aplasia
    Intervention:   Biological: Thrombosomes
    Sponsors:   Cellphire, Inc.;   Department of Health and Human Services
    Recruiting

  • Conditions:   Myelodysplastic Syndrome (MDS);   Hematologic Neoplasms;   Hematologic Diseases;   Severe Aplastic Anemia
    Intervention:   Drug: Cord Blood Transplant
    Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Leukemia in Remission;   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Acute Myeloid Leukemia With FLT3/ITD Mutation;   Acute Myeloid Leukemia With Gene Mutations;   Aplastic Anemia;   B-Cell Non-Hodgkin Lymphoma;   CD40 Ligand Deficiency;   Chronic Granulomatous Disease;   Chronic Leukemia in Remission;   Chronic Lymphocytic Leukemia;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Congenital Amegakaryocytic Thrombocytopenia;   Congenital Neutropenia;   Congenital Pure Red Cell Aplasia;   Glanzmann Thrombasthenia;   Immunodeficiency Syndrome;   Myelodysplastic Syndrome;   Myelofibrosis;   Myeloproliferative Neoplasm;   Paroxysmal Nocturnal Hemoglobinuria;   Plasma Cell Myeloma;   Polycythemia Vera;   Recurrent Non-Hodgkin Lymphoma;   Refractory Non-Hodgkin Lymphoma;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndrome;   Severe Aplastic Anemia;   Shwachman-Diamond Syndrome;   Sickle Cell Disease;   T-Cell Non-Hodgkin Lymphoma;   Thalassemia;   Waldenstrom Macroglobulinemia;   Wiskott-Aldrich Syndrome
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Procedure: Peripheral Blood Stem Cell Transplantation;   Radiation: Total-Body Irradiation
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Diamond Blackfan Anemia;   Dyskeratosis Congenita;   Fanconi Anemia;   Shwachman Diamond Syndrome;   Inherited Bone Marrow Failure Syndrome, Aplastic Anemia
    Intervention:  
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Bone Marrow Failure Syndromes
    Interventions:   Other: MRD-BMT with Fludarabine-based RIC for Acquired AA;   Other: MRD-BMT with Fludarabine-based RIC for iBMF with trilineage aplasia;   Other: MRD-BMT with Fludarabine-based RIC for iBMF without trilineage aplasia
    Sponsor:   Children's Hospital of Philadelphia
    Recruiting

  • Conditions:   Bone Marrow Failure Syndrome;   Severe Aplastic Anemia;   Severe Congenital Neutropenia;   Amegakaryocytic Thrombocytopenia;   Diamond-Blackfan Anemia;   Schwachman Diamond Syndrome;   Primary Immunodeficiency Syndromes;   Acquired Immunodeficiency Syndromes;   Histiocytic Syndrome;   Familial Hemophagocytic Lymphocytosis;   Lymphohistiocytosis;   Macrophage Activation Syndrome;   Langerhans Cell Histiocytosis (LCH);   Hemoglobinopathies;   Sickle Cell Disease;   Sickle Cell-beta-thalassemia
    Intervention:   Biological: CD34 Stem Cell Selection Therapy
    Sponsor:   Diane George, MD
    Recruiting

  • Conditions:   Chronic Myelogenous Leukemia (CML);   Acute Myelogenous Leukemia (AML);   Myelodysplastic Syndrome;   Multiple Myeloma;   Hodgkin Lymphoma;   Non-Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia (CLL);   Acute Lymphocytic Leukemia (ALL);   Severe Aplastic Anemia
    Intervention:   Genetic: umbilical cord blood (UCB)
    Sponsor:   West Virginia University
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Acute Myeloid Leukemia in Remission;   Aplastic Anemia;   Chronic Myelomonocytic Leukemia;   Hodgkin Lymphoma;   Indolent Non-Hodgkin Lymphoma;   Malignant Neoplasm;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Plasma Cell Myeloma;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Ring Sideroblasts;   Refractory Cytopenia With Multilineage Dysplasia;   Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts
    Interventions:   Drug: Fludarabine;   Radiation: Total-Body Irradiation;   Biological: T Cell-Depleted Donor Lymphocyte Infusion;   Drug: Cyclophosphamide;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
    Sponsor:   Sidney Kimmel Cancer Center at Thomas Jefferson University
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Acute Myeloid Leukemia in Remission;   Aplastic Anemia;   Bone Marrow Failure;   Chronic Lymphocytic Leukemia;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Donor;   Follicular Lymphoma;   Hematopoietic Cell Transplantation Recipient;   Hodgkin Lymphoma;   Mantle Cell Lymphoma;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Near Complete Response of Multiple Myeloma or Plasma Cell Leukemia;   Non-Hodgkin Lymphoma;   Partial Response of Multiple Myeloma or Plasma Cell Leukemia;   Plasma Cell Myeloma
    Interventions:   Biological: Anti-Thymocyte Globulin;   Drug: Cyclophosphamide;   Biological: Cytokine-treated Veto Cells;   Drug: Fludarabine;   Procedure: Peripheral Blood Stem Cell Transplantation;   Radiation: Total-Body Irradiation
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Aplastic Anemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Myelodysplastic Syndromes;   Chronic Eosinophilic Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Neutrophilic Leukemia;   Essential Thrombocythemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Juvenile Myelomonocytic Leukemia;   Mastocytosis;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Polycythemia Vera;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Anemia;   Refractory Anemia With Ringed Sideroblasts;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Secondary Myelodysplastic Syndromes;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Waldenström Macroglobulinemia
    Interventions:   Drug: Fludarabine;   Drug: Busulfan;   Radiation: Total Body Irradiation (TBI);   Biological: Donor Lymphocyte Infusion (DLI);   Drug: Cyclophosphamide (CY);   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Device: Allogeneic hematopoietic stem cell transplantation;   Procedure: Peripheral blood stem cell transplantation (PBSCT)
    Sponsor:   Sidney Kimmel Cancer Center at Thomas Jefferson University
    Recruiting

  • Conditions:   Lymphoma;   Leukemia;   Myeloma;   Myelodysplastic Syndromes;   Severe Aplastic Anemia;   Primary Immune Deficiency;   Graft Vs Host Disease
    Intervention:   Biological: CD62L- Tem
    Sponsors:   University College, London;   Medical Research Council
    Not yet recruiting

  • Conditions:   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Myelodysplastic Syndromes;   Non-hodgkin Lymphoma;   Hodgkin Lymphoma;   Acquired Aplastic Anemia;   Sickle Cell Disease
    Intervention:   Other: Donor Search Prognosis Score
    Sponsors:   Center for International Blood and Marrow Transplant Research;   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI);   Blood and Marrow Transplant Clinical Trials Network;   National Marrow Donor Program;   Medical College of Wisconsin
    Not yet recruiting

  • Conditions:   Acute Myeloid Leukemia in Remission;   Adult Acute Lymphoblastic Leukemia in Complete Remission;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission;   Chronic Myelomonocytic Leukemia in Remission;   Graft Versus Host Disease;   Hodgkin Lymphoma;   Minimal Residual Disease;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Non-Hodgkin Lymphoma;   Plasma Cell Myeloma;   Severe Aplastic Anemia;   Waldenstrom Macroglobulinemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan Hydrochloride;   Drug: Mycophenolate Mofetil;   Drug: Sirolimus;   Radiation: Total-Body Irradiation
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Hematologic Malignancies;   Inherited Disorders of Metabolism;   Inherited Abnormalities of Platelets;   Histiocytic Disorders;   Acute Myelogenous Leukemia (AML or ANLL);   Acute Lymphoblastic Leukemia (ALL);   Other Acute Leukemia;   Chronic Myelogenous Leukemia (CML);   Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases;   Other Leukemia;   Hodgkin Lymphoma;   Non-hodgkin Lymphoma;   Multiple Myeloma/ Plasma Cell Disorder (PCD);   Inherited Abnormalities of Erythrocyte Differentiation or Function;   Disorders of the Immune System;   Automimmune Diseases;   Severe Aplastic Anemia
    Intervention:   Drug: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
    Sponsors:   Center for International Blood and Marrow Transplant Research;   National Marrow Donor Program
    Recruiting

  • Condition:   Telomere Disease
    Intervention:   Drug: Danazol
    Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Conditions:   Immune Thrombocytopenia;   Autoimmune Hemolytic Anemia;   Evan Syndrome;   Primary Immunodeficiency
    Intervention:   Diagnostic Test: potential biomarkers
    Sponsor:   Medical University of Graz
    Recruiting

  • Condition:   Leukemia
    Interventions:   Drug: Rituximab;   Drug: Melphalan;   Drug: Fludarabine;   Radiation: Total body irradiation (TBI);   Procedure: Stem Cell Infusion;   Drug: Cyclophosphamide;   Drug: G-CSF
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting

  • Conditions:   Chronic Myeloid Leukemia (CML);   Acute Myelogenous Leukemia (AML);   Myelodysplastic Syndrome (MDS);   Juvenile Myelomonocytic Leukemia (JMML);   Acute Lymphoblastic Leukemia (ALL);   Lymphoma (Hodgkin's and Non-Hodgkin's)
    Interventions:   Device: CliniMACS CD34+ Reagent System;   Drug: Thiotepa;   Drug: Cyclophosphamide;   Drug: Alemtuzumab;   Drug: Tacrolimus;   Drug: Melphalan;   Drug: Busulfan;   Drug: Fludarabine;   Drug: Methylprednisolone
    Sponsor:   Diane George, MD
    Recruiting

  • Conditions:   Hematologic Malignancies;   Inborn Errors of Metabolism Disorders;   Immune Deficiencies
    Intervention:   Biological: CliniMACS CD34 Reagent System
    Sponsors:   Joanne Kurtzberg, MD;   Duke University;   Miltenyi Biotec, Inc.
    Available

  • Conditions:   Anemia;   Blood Disease
    Intervention:  
    Sponsors:   Northwell Health;   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Conditions:   Autoimmune Hemolytic Anemia;   Pure Red Cell Aplasia;   Evans Syndrome
    Intervention:   Drug: Tacrolimus
    Sponsor:   Peking Union Medical College Hospital
    Not yet recruiting

Login to Get Started